# Germany Microbiome Sequencing Services Market > Germany Microbiome Sequencing Services Market Research Report: By Technology (Sequencing by Litigation (SBL), Sequencing by Synthesis (SBS), Short Gun Sequencing, Targeted Gene Sequencing, RNA Sequencing, Others) and By Application (Gastrointestinal Diseases, Infectious Diseases, CNS Diseases, Oncology, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 16.86% - **2024:** $ 114.58 Million - **2025:** $ 133.9 Million - **2035:** $ 636.08 Million - **Key Players:** Illumina (US), Thermo Fisher Scientific (US), Zymo Research (US), Qiagen (DE), Genomatix (DE), Microbiome Insights (CA), Second Genome (US), CosmosID (US) **Report ID:** MRFR/HS/52146-HCR · **Pages:** 200 · **Author:** Rahul Gotadki & Garvit Vyas · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/germany-microbiome-sequencing-services-market-53908 --- ## Market Summary ## **Germany Microbiome Sequencing Services Market Overview****:** As per MRFR analysis, the Germany Microbiome Sequencing Services Market Size was estimated at 94.63 (USD Million) in 2023.The Germany Microbiome Sequencing Services Market Industry is expected to grow from 104(USD Million) in 2024 to 520 (USD Million) by 2035. The Germany Microbiome Sequencing Services Market CAGR (growth rate) is expected to be around 15.756% during the forecast period (2025 - 2035). ### **Key Germany Microbiome Sequencing Services Market Trends Highlighted** The Germany Microbiome Sequencing Services Market is experiencing substantial trends that are being driven by the growing investments in the biotech and healthcare sectors. The human microbiome's function in health and disease is being further investigated as a result of the growing interest in personalized medicine. The robust healthcare system of Germany, which prioritizes innovative treatment options, substantiates this assertion. Additionally, the frequency of collaborations between academic institutions and biotech companies is increasing, which is contributing to the advancement of microbiome research.  The increasing demand for microbiome analysis in sectors such as agriculture and food safety presents an opportunity for exploration, as agricultural practices increasingly consider beneficial microorganisms for crop health. In the German market, there has been a recent increase in consumer awareness of gut health, which has led to a surge in the number of companies that offer microbiome analysis and associated products. Germany's status as a leader in scientific innovation is further bolstered by the regulatory support provided by the European Union, which creates a favorable environment for microbiome research and its applications.  German healthcare providers are increasingly incorporating microbiome sequencing into their routine diagnostics and health management strategies to improve preventive care. Furthermore, the expansion of microbiome studies is being facilitated by funding opportunities from government initiatives, which are laying a fertile foundation for established firms and startups that are anxious to capitalize on this emerging field.Germany is positioned as a critical participant in the evolving microbiome sequencing services landscape as a result of this combination of research advancement and application development. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** ## **Germany Microbiome Sequencing Services Market Drivers** ### **Rising Interest in Personalized Medicine and Health** The drive towards personalized medicine is a significant factor in the growth of the Germany Microbiome Sequencing Services Market Industry. With more healthcare providers and laboratories focusing on individualized treatment plans, the demand for advanced microbiome sequencing services is increasing. A report from the German Ministry of Health indicates a growing trend in the implementation of personalized healthcare strategies, with approximately 23% of all medical facilities adopting methods that consider individual genetic and microbiome profiles.Established organizations such as Bayer AG and BioNTech are heavily investing in Research and Development efforts aimed at harnessing microbiome data to tailor therapies for various diseases. This focus on personalized treatment options created an estimated market expansion in this sector, highlighting the key role of microbiome sequencing in future healthcare developments. ### **Increasing Prevalence of Chronic Diseases** The increasing rate of chronic diseases, including diabetes and cardiovascular issues, significantly influences the Germany Microbiome Sequencing Services Market. According to data from the Federal Statistical Office of Germany, the prevalence of diabetes has risen by about 16% in the past five years, affecting nearly 6 million people in the country. With the chronic disease management sector increasingly recognizing the role of gut health in disease progression, companies such as Qiagen and Thermo Fisher Scientific are expanding their microbiome analysis capabilities.This trend enhances the market demand for microbiome sequencing services as healthcare providers seek insights into how microbiome composition can impact the management and treatment of chronic conditions. ### **Advancements in Sequencing Technologies** Advancements in sequencing technologies are propelling the Germany Microbiome Sequencing Services Market forward. Next-generation sequencing (NGS) has become faster, cheaper, and more accessible. The German government is supporting biotechnology innovation through initiatives like the BioEconomy Strategy, which aims to promote the development of advanced sequencing technologies and related applications. As a result, organizations such as the German Center for Infection Research are conducting advanced studies, with a focus on microbiome research and its applications in clinical settings.This technological evolution in microbiome sequencing not only lowers research costs but also increases the quality and volume of data produced, boosting demand within the industry. ### **Growing Investment in Research and Development** There is a substantial growth in investment for Research and Development in microbiome-related projects, which directly benefits the Germany Microbiome Sequencing Services Market Industry. Recent funding initiatives by the Federal Ministry of Education and Research in Germany indicate a rise in budget allocations towards life sciences, with over 2 billion euros directed towards microbial and genomic research from 2020 to 2025. Companies such as Evotec and Genomatix have recognized this potential and are partnering with universities to explore innovations in microbiome research.This focused investment is driving the need for microbiome sequencing services as it leads to groundbreaking scientific discoveries and enhances the understanding of the microbiome’s role in health, thus stimulating further market growth. ## **Germany Microbiome Sequencing Services Market Segment Insights****:** ### **Microbiome Sequencing Services Market Technology Insights** The Germany Microbiome Sequencing Services Market under the Technology segment exhibits a dynamic landscape, driven by advancements in sequencing methodologies that enhance research and clinical applications. Among these, Sequencing by Litigation (SBL) and Sequencing by Synthesis (SBS) are pivotal techniques that enable detailed genomic analysis, essential for understanding microbial communities' complexity and functionality.  The adaptability of Short Gun Sequencing provides comprehensive insights into the genetic diversity within samples, making it a crucial choice for researchers focusing on metagenomics.Targeted Gene Sequencing continues to gain traction for its precision in analyzing specific genes of interest, aiding in diagnostics and therapeutic development. RNA Sequencing holds particular significance as it offers a thorough examination of gene expression patterns, allowing scientists to investigate the functional elements of microbiomes. Collectively, these technologies are instrumental in unraveling the intricate associations between microbiomes and human health, agriculture, and environmental sustainability. The significant focus on leveraging these platforms in Germany aligns with national priorities in biotechnology and healthcare innovation, fostering a robust environment for growth and collaboration among academic institutions, industry stakeholders, and government initiatives.Overall, the technological advancements in the Germany Microbiome Sequencing Services Market not only spur research but also present new opportunities for addressing complex health challenges, demonstrating the country's commitment to remaining at the forefront of biotechnology. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** ### **Microbiome Sequencing Services Market Application Insights** The Germany Microbiome Sequencing Services Market is primarily driven by its diverse applications, significantly impacting various medical fields. The segmentation within the Application sector includes critical areas such as Gastrointestinal Diseases, Infectious Diseases, Central Nervous System (CNS) Diseases, Oncology, and Others. Gastrointestinal Diseases hold a prominent role due to the rising prevalence of conditions like Irritable Bowel Syndrome and Crohn’s disease, which underscores the necessity for advanced microbiome analysis. Infectious Diseases are gaining increased attention as microbiome sequencing aids in understanding microbial resistance and pathogen identification, enhancing treatment protocols. The significance of CNS Diseases is notable, as emerging research highlights the microbiome's potential influence on neurological conditions like depression and Alzheimer’s disease. Oncology stands out as well since understanding tumor microenvironments through microbiome analysis could lead to breakthrough therapies. The "Others" category encompasses various applications that further enhance the capabilities of microbiome sequencing, creating ample opportunities for innovation and research. Germany’s strong healthcare infrastructure and investment in Research and Development in microbiome initiatives contribute to the growing importance of these applications, showcasing the country as an emerging leader in microbiome exploration and its therapeutic potential. ## **Germany Microbiome Sequencing Services Market Key Players and Competitive Insights****:** The Germany Microbiome Sequencing Services Market is characterized by a dynamic competitive landscape shaped by advancements in technology, growing awareness among healthcare providers and researchers, and increasing investments in microbiome research. With the rising recognition of the microbiome's role in human health, businesses within this sector are striving to enhance their service offerings, expand market reach, and cater to diverse client needs. Key players are focusing on innovations such as next-generation sequencing technologies to provide comprehensive insights into microbial communities, aiding in areas like personalized medicine, diagnostics, and nutritional science.  The competition is further intensifying as new entrants emerge and established companies refine their strategies to maintain or gain a competitive edge through improved customer experiences and collaboration with research institutions.Zymo Research is a prominent player in the Germany Microbiome Sequencing Services Market, known for its innovative solutions that facilitate microbiome research. Their strengths lie in their advanced genomic tools and extensive experience in the field, which enable them to provide high-quality sequencing services tailored to the specific requirements of their clients. Zymo Research presents a strong market presence with a focus on enhancing precision in microbiome analysis.  The company's ability to streamline workflows while ensuring reproducibility and reliability in results contributes to its competitive advantage. Additionally, Zymo Research’s vast library of protocols and reagents makes it easier for researchers to conduct studies effectively in the growing microbiome sector, establishing a trustworthy brand reputation among German researchers and healthcare professionals alike.Element Biosciences is carving out a significant presence in the Germany Microbiome Sequencing Services Market with its unique product offerings aimed at optimizing sequencing capabilities. The company stands out through its innovative technology that provides fast and cost-effective sequencing options, catering to an array of research needs in the microbiomics field. Element Biosciences emphasizes scalability and flexibility in its services, enhancing laboratory efficiency and throughput for its clients. The company’s key services, including targeted sequencing and metagenomic analysis, offer researchers a comprehensive understanding of microbial ecosystems.  As Element Biosciences continues to expand its footprint in Germany, strategic partnerships and potential mergers and acquisitions could further bolster its position within the market, allowing for greater resource sharing and innovation through collaborative efforts. This proactive approach enhances their competitive standing and illustrates their commitment to driving advancements in microbiome research within the region. ### **Key Companies in the Germany Microbiome Sequencing Services Market Include:** - Zymo Research - Element Biosciences - Bio-Rad Laboratories - Roche - Qiagen - Takara Bio - Thermo Fisher Scientific - Illumina - Novogene - genomatix - Oxford Nanopore Technologies - Genomatix - BGI Genomics ## **Germany Microbiome Sequencing Services Market Industry Developments** The Germany Microbiome Sequencing Services Market has recently experienced notable developments. In August 2023, Illumina announced enhancements to its sequencing technology, aimed at improving accuracy and reducing costs for microbiome studies, which is expected to boost research capabilities in Germany. Meanwhile, Thermo Fisher Scientific has reported significant growth, enhancing its analytical services to cater to increasing demands for microbiome sequencing. Additionally, in October 2023, Zymo Research introduced a new product line specifically designed for gut microbiome analysis, further solidifying its position in the market.  Regarding mergers and acquisitions, in September 2023, BioRad Laboratories acquired a minor stake in a German biotech firm focused on microbiome diagnostics, enhancing its offerings in the European market. The market has witnessed steady growth due to increasing investment in biotechnology and healthcare, with key players like Qiagen and Roche expanding their operations. The overall valuation of the market is anticipated to increase as more research institutions in Germany focus on microbiome research, driven by government funding initiatives tailored towards healthcare innovation, particularly in understanding gut health and its implications on overall wellness. ## **Germany Microbiome Sequencing Services Market Segmentation Insights** ### **Microbiome Sequencing Services Market Technology****Outlook** - Sequencing by Litigation (SBL) - Sequencing by Synthesis (SBS) - Short Gun Sequencing - Targeted Gene Sequencing - RNA Sequencing - Others ### **Microbiome Sequencing Services Market Application****Outlook** - Gastrointestinal Diseases - Infectious Diseases - CNS Diseases - Oncology - Others ## Market Drivers ### Rising Health Awareness The increasing awareness of health and wellness among the German population is driving the microbiome sequencing-services market. Consumers are becoming more informed about the role of gut health in overall well-being, leading to a surge in demand for microbiome analysis. This trend is reflected in the growing number of individuals seeking personalized health insights through microbiome testing. In 2025, the market is projected to grow by approximately 15%, indicating a robust interest in understanding the microbiome's impact on health. As more people recognize the connection between diet, lifestyle, and microbiome composition, the demand for sequencing services is likely to expand, further propelling the market forward. ### Increased Investment in Biotechnology The microbiome sequencing-services market is benefiting from increased investment in the biotechnology sector in Germany. Venture capital and government funding are being directed towards companies specializing in microbiome research and sequencing technologies. This influx of capital is fostering innovation and enabling the development of new sequencing services tailored to specific health needs. In 2025, it is projected that investment in biotechnology related to microbiome research will grow by 25%, which could lead to the emergence of novel applications and services in the microbiome sequencing market, further driving its expansion. ### Technological Innovations in Sequencing Technological innovations in sequencing technologies are playing a crucial role in shaping the microbiome sequencing-services market. The development of next-generation sequencing (NGS) and other advanced methodologies has made microbiome analysis more accessible and cost-effective. In Germany, the cost of sequencing has decreased by approximately 40% over the past few years, making it feasible for a larger segment of the population to utilize these services. This trend is likely to continue, as ongoing improvements in technology enhance the speed and accuracy of microbiome sequencing, thereby attracting more consumers and healthcare professionals to the market. ### Advancements in Research and Development Ongoing advancements in research and development within the field of microbiome science are significantly influencing the microbiome sequencing-services market. German research institutions and universities are increasingly focusing on microbiome studies, leading to innovative sequencing technologies and methodologies. This research is not only enhancing the accuracy of microbiome analysis but also expanding its applications in various fields, including nutrition, mental health, and chronic disease management. The investment in R&D is expected to increase by around 20% in the coming years, which may result in more sophisticated sequencing services and a broader understanding of microbiome functions, thereby stimulating market growth. ### Growing Demand from Healthcare Providers Healthcare providers in Germany are increasingly recognizing the value of microbiome sequencing in clinical practice, which is driving the microbiome sequencing-services market. The integration of microbiome analysis into routine healthcare is becoming more prevalent, as practitioners seek to offer personalized treatment plans based on individual microbiome profiles. This shift is supported by a growing body of evidence linking microbiome health to various diseases, including obesity and autoimmune disorders. As of 2025, it is estimated that around 30% of healthcare providers will incorporate microbiome sequencing into their services, indicating a significant market opportunity for sequencing service providers. ## Future Outlook The [Microbiome Sequencing Services Market](https://www.marketresearchfuture.com/reports/microbiome-sequencing-services-market-7532) is projected to grow at a 16.86% CAGR from 2025 to 2035, driven by advancements in technology, increasing health awareness, and rising demand for personalized medicine. **New opportunities:** - Development of subscription-based microbiome analysis services for consumers. - Partnerships with healthcare providers for integrated microbiome health solutions. - Investment in AI-driven data analytics for enhanced microbiome interpretation. By 2035, the market is expected to be robust, driven by innovation and strategic partnerships. ## Segment Insights ### By Technology: Sequencing by Synthesis (Largest) vs. RNA Sequencing (Fastest-Growing) The Germany microbiome sequencing-services market displays a diverse array of technologies, with Sequencing by Synthesis (SBS) leading in market share, significantly outperforming competing methods. Other notable techniques include Sequencing by Litigation (SBL) and Short Gun Sequencing, which capture a growing segment of the market. Targeted Gene Sequencing and Others also contribute, but their shares remain relatively small in comparison to the dominant SBS. Growth trends in the market indicate a strong shift towards RNA Sequencing, identified as the fastest-growing segment. This surge is driven by increasing research activities focusing on gene expression studies, along with advancements in sequencing technologies that enhance accuracy and reduce costs. These factors are propelling researchers and institutions to invest more in RNA Sequencing, indicative of a broader trend towards molecular biology applications in the microbiome landscape. Technology: Sequencing by Synthesis (Dominant) vs. RNA Sequencing (Emerging) Sequencing by Synthesis (SBS) is the dominant technology in the Germany microbiome sequencing-services market, known for its high throughput and accuracy. This method allows for extensive DNA sequencing and is favored in many research and clinical applications, positioning it as a cornerstone of the market. Conversely, RNA Sequencing is emerging rapidly, appealing primarily due to its capacity to analyze gene expression and provide insights into functional genomics. As researchers seek to understand the complexities of microbiomes, RNA Sequencing is gaining traction, supported by advancements in processing capabilities and a growing body of research emphasizing its importance in translational studies. ### By Application: Gastrointestinal Diseases (Largest) vs. Oncology (Fastest-Growing) In the Germany microbiome sequencing-services market, the application segment for gastrointestinal diseases holds the largest share, reflecting the significant prevalence of these conditions among the population. This segment showcases robust demand fueled by increasing awareness and the necessity for advanced diagnostic tools that leverage microbiome data. Other applications, such as infectious diseases, CNS diseases, and oncology, also contribute to market dynamics but are trailing in terms of overall share. Oncology is emerging as the fastest-growing segment, driven by advancements in personalized medicine and the growing emphasis on understanding tumor microenvironments through microbiome analysis. As healthcare providers increasingly adopt microbiome sequencing to explore its potential in cancer therapeutics, this segment is likely to see substantial growth. In contrast, while gastrointestinal diseases remain dominant, demand for innovative solutions across other segments is also rising, highlighting a shift in healthcare strategies that integrate microbiome insights. Gastrointestinal Diseases (Dominant) vs. Oncology (Emerging) Gastrointestinal diseases represent a dominant application segment in the Germany microbiome sequencing-services market, heavily influenced by the increasing incidence of conditions such as IBS and Crohn's disease. Healthcare providers prioritize microbiome insights to enhance patient care and offer targeted treatments, fostering a strong demand for sequencing services. Conversely, oncology is categorized as an emerging segment, with a focus on utilizing microbiome data to unravel the complexities of tumor biology and patient responses to therapies. This emerging trend is accompanied by a rising interest in integrating microbiome analysis with traditional oncology approaches, presenting opportunities for growth as research and clinical applications expand. ## Competitive Benchmarking The microbiome sequencing-services market in Germany is characterized by a dynamic competitive landscape, driven by increasing demand for personalized medicine and advancements in genomic technologies. Key players such as Illumina (US), Qiagen (DE), and Thermo Fisher Scientific (US) are at the forefront, leveraging their technological expertise and extensive product portfolios to capture market share. Illumina (US) focuses on innovation in sequencing technology, while Qiagen (DE) emphasizes its strong presence in molecular diagnostics. Thermo Fisher Scientific (US) adopts a strategy of regional expansion, enhancing its service offerings to meet local market needs. Collectively, these strategies foster a competitive environment that is both innovative and responsive to emerging trends in healthcare.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market appears moderately fragmented, with several players vying for dominance. However, the collective influence of major companies like Zymo Research (US) and Genomatix (DE) contributes to a competitive structure that encourages collaboration and innovation, as these firms often engage in partnerships to expand their technological capabilities and market reach. In October Illumina (US) announced a strategic partnership with a leading German research institution to develop next-generation sequencing applications tailored for microbiome research. This collaboration is expected to enhance Illumina's product offerings and solidify its position as a leader in the microbiome sequencing space. The strategic importance of this partnership lies in its potential to accelerate innovation and improve access to advanced sequencing technologies for researchers in Germany. In September Qiagen (DE) launched a new bioinformatics platform designed to streamline microbiome data analysis. This platform aims to provide researchers with more efficient tools for interpreting complex microbiome data, thereby enhancing the overall research process. The introduction of this platform signifies Qiagen's commitment to integrating advanced technology into its service offerings, which may lead to increased customer loyalty and market penetration. In August Thermo Fisher Scientific (US) expanded its product line by introducing a new suite of microbiome analysis kits aimed at clinical laboratories. This move is indicative of the company's strategy to diversify its offerings and cater to the growing demand for microbiome-related diagnostics. By enhancing its product portfolio, Thermo Fisher Scientific (US) positions itself to capture a larger share of the market, particularly in clinical applications. As of November current trends in the microbiome sequencing-services market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence (AI) in data analysis. Strategic alliances among key players are shaping the competitive landscape, fostering innovation and collaboration. Looking ahead, it is likely that competitive differentiation will increasingly hinge on technological advancements and supply chain reliability, rather than solely on price. This shift suggests a future where innovation and quality become the primary drivers of market success. ## Recent News & Developments The Germany Microbiome Sequencing Services Market has recently experienced notable developments. In August 2023, Illumina announced enhancements to its sequencing technology, aimed at improving accuracy and reducing costs for microbiome studies, which is expected to boost research capabilities in Germany. Meanwhile, Thermo Fisher Scientific has reported significant growth, enhancing its analytical services to cater to increasing demands for microbiome sequencing. Additionally, in October 2023, Zymo Research introduced a new product line specifically designed for gut microbiome analysis, further solidifying its position in the market.  Regarding mergers and acquisitions, in September 2023, BioRad Laboratories acquired a minor stake in a German biotech firm focused on microbiome diagnostics, enhancing its offerings in the European market. The market has witnessed steady growth due to increasing investment in biotechnology and healthcare, with key players like Qiagen and Roche expanding their operations. The overall valuation of the market is anticipated to increase as more research institutions in Germany focus on microbiome research, driven by government funding initiatives tailored towards healthcare innovation, particularly in understanding gut health and its implications on overall wellness. ## Report Scope | MARKET SIZE 2024 | 114.58(USD Million) | | --- | --- | | MARKET SIZE 2025 | 133.9(USD Million) | | MARKET SIZE 2035 | 636.08(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 16.86% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Illumina (US), Thermo Fisher Scientific (US), Zymo Research (US), Qiagen (DE), Genomatix (DE), Microbiome Insights (CA), Second Genome (US), CosmosID (US) | | Segments Covered | Technology, Application | | Key Market Opportunities | Growing demand for personalized medicine drives innovation in microbiome sequencing-services market. | | Key Market Dynamics | Rising demand for personalized medicine drives innovation in microbiome sequencing-services and enhances competitive dynamics. | | Countries Covered | Germany | ## Frequently Asked Questions **Q: What is the current valuation of the microbiome sequencing-services market in Germany?** A: The market valuation was $114.58 Million in 2024. **Q: What is the projected market size for the microbiome sequencing-services market in Germany by 2035?** A: The projected valuation for 2035 is $636.08 Million. **Q: What is the expected CAGR for the microbiome sequencing-services market in Germany from 2025 to 2035?** A: The expected CAGR during the forecast period is 16.86%. **Q: Which companies are the key players in the microbiome sequencing-services market in Germany?** A: Key players include Illumina, Thermo Fisher Scientific, Zymo Research, Qiagen, Genomatix, Microbiome Insights, Second Genome, and CosmosID. **Q: What are the main technology segments in the microbiome sequencing-services market in Germany?** A: Main technology segments include Sequencing by Litigation, Sequencing by Synthesis, Short Gun Sequencing, Targeted Gene Sequencing, RNA Sequencing, and Others. **Q: What was the market value for Sequencing by Synthesis in 2024?** A: The market value for Sequencing by Synthesis was $30.0 Million to $150.0 Million. **Q: Which application segment is expected to have the highest market value in the microbiome sequencing-services market in Germany?** A: The Oncology application segment is expected to have the highest market value, ranging from $30.0 Million to $180.0 Million. **Q: What was the market value for Gastrointestinal Diseases in 2024?** A: The market value for Gastrointestinal Diseases was $25.0 Million to $140.0 Million. **Q: How does the market for RNA Sequencing compare to other technology segments in Germany?** A: The market value for RNA Sequencing ranged from $15.0 Million to $80.0 Million, indicating a moderate position among technology segments. **Q: What is the potential growth outlook for the microbiome sequencing-services market in Germany?** A: The market appears poised for substantial growth, with projections indicating a significant increase by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/germany-microbiome-sequencing-services-market-53908*